CN105535448A - Traditional Chinese medicine composition for treating child myasthenia gravis - Google Patents

Traditional Chinese medicine composition for treating child myasthenia gravis Download PDF

Info

Publication number
CN105535448A
CN105535448A CN201610129957.5A CN201610129957A CN105535448A CN 105535448 A CN105535448 A CN 105535448A CN 201610129957 A CN201610129957 A CN 201610129957A CN 105535448 A CN105535448 A CN 105535448A
Authority
CN
China
Prior art keywords
parts
chinese medicine
radix
medicine composition
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201610129957.5A
Other languages
Chinese (zh)
Other versions
CN105535448B (en
Inventor
乞国艳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201610129957.5A priority Critical patent/CN105535448B/en
Publication of CN105535448A publication Critical patent/CN105535448A/en
Application granted granted Critical
Publication of CN105535448B publication Critical patent/CN105535448B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/233—Bupleurum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A61K36/344—Codonopsis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/40—Cornaceae (Dogwood family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/486—Millettia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704—Polygonum, e.g. knotweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A61K36/746—Morinda
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A61K36/815—Lycium (desert-thorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/894—Dioscoreaceae (Yam family)
    • A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8968—Ophiopogon (Lilyturf)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention discloses traditional Chinese medicine composition for treating child myasthenia gravis. The traditional Chinese medicine composition is prepared from Chinese herbal raw materials in parts by weight as follows: 10-120 parts of membranous milkvetch roots, 10-30 parts of pilose asiabell roots, 10-20 parts of largehead atractylodes rhizomes, 5-8 parts of Chinese thorowax roots, 5-8 parts of largetrifoliolious bugbane rhizomes, 5-10 parts of Chinese angelica, 5-10 parts of common macrocarpium fruits, 5-10 parts of medicinal indianmulberry roots, 5-10 parts of south dodder seeds, 8-24 parts of Chinese yams, 6-30 parts of prepared tuber fleeceflower roots, 5-12 parts of suberect spatholobus stems, 5-12 parts of fructus lycii, 3-6 parts of liquorice, 3-6 parts of tangerine peel and 3-10 parts of dwarf lilyturf tubers. The traditional Chinese medicine composition is reasonably prepared, does not have toxic or side effects, is convenient to process, low in cost and suitable for popularization and use in clinic and has a remarkable treatment effect on child myasthenia gravis.

Description

A kind of Chinese medicine composition for the treatment of myasthenia gravis in children:
Technical field
The invention belongs to drug world, relate to a kind of Chinese medicine composition for the treatment of myasthenia gravis in children:.
Background technology
Myasthenia gravis is one of intractable disease of nervous system, and its disease shows as: one-sided or bilateral blepharoptosis, tetraparesis are unable, dysphagia and asaphia.
People use anticholinergic medicine, thymusectomy, radiotherapy three kinds of method treatment myasthenia graviss traditionally, but cholinolytic enzyme medicine as neostigmine, pyridostigmine etc. be a kind of temporary, local onset medicine, the outbreak delaying the state of an illness that can only be of short duration, long-term prescription can cause acetylcholinergic receptor in human body to destroy, and the state of an illness is more serious.In medical applications, adopting cholinolytic enzyme medicine to occur, the example of serious side effects also has report more.Curative effect is undesirable on the one hand for the operation method such as thymusectomy, radiotherapy, and effects more than five terms has to be seen; Adopt operation method only can be used for the Patients With Myasthenia Gravis having occurred this symptom of thymus neoplasms, narrow application range on the other hand.In recent years emerging plasma exchange rule only can be used for critical Patients With Myasthenia Gravis, and its curative effect also can only maintain about two weeks, costly, and practical value is low.
The traditional Chinese medical science is thought, myasthenia gravis belongs to the flaccidity symptom in traditional Chinese medical science category, therefore adopts treatment by Chinese herbs to have certain effect pointedly.
Summary of the invention
The object of the present invention is to provide a kind of Chinese medicine composition for the treatment of myasthenia gravis in children:, Chinese medicine composition preparation method of the present invention is simple, and good effect, use safety, has no side effect, and is adapted at extensive use clinically.
To achieve these goals, present invention employs following technical scheme:
The invention provides a kind of Chinese medicine composition for the treatment of myasthenia gravis in children:, described Chinese medicine composition is prepared from by the raw material of Chinese medicine of following weight: the Radix Astragali (Astragalusmembranaceus (Fisch.) Bge.) 10-120 part, Radix Codonopsis (RADIXCODONOPSIS) 10-30 part, the Rhizoma Atractylodis Macrocephalae (Atractylodesmacrocephala) 10-20 part, Radix Bupleuri (RadixBupleuri) 5-8 part, Rhizoma Cimicifugae (RHIZOMACIMICIFUGAE) 5-8 part, Radix Angelicae Sinensis (Angelicasinensis (Oliv.) Diels.) 5-10 part, Fructus Corni (CornusofficinalisSieb.EtZucc.) 5-10 part, Radix Morindae Officinalis (Morinda) 5-10 part, Semen Cuscutae (CuscutachinensisLam.) 5-10 part, Rhizoma Dioscoreae (Dioscoreaopposita) 8-24 part, Radix Polygoni Multiflori Preparata (cntRdoa) 6-30 part, Caulis Spatholobi (MillettiareticuiataBenth.) 5-12 part, Fructus Lycii (FructusLycii) 5-12 part, Radix Glycyrrhizae (GlycyrrizaUralensisFisch.G.GlabraL.) 3-6 part, Pericarpium Citri Reticulatae (PERICARPIUM) 3-6 part, Radix Ophiopogonis (Ophiopogonjaponicus (Linn.f.) Ker-Gawl.) 3-10 part.
Further, described Chinese medicine composition is formulated by the raw material of Chinese medicine of following weight: the Radix Astragali 60 parts, Radix Codonopsis 20 parts, the Rhizoma Atractylodis Macrocephalae 15 parts, Radix Bupleuri 6 parts, Rhizoma Cimicifugae 6 parts, Radix Angelicae Sinensis 7 parts, Fructus Corni 7 parts, Radix Morindae Officinalis 7 parts, Semen Cuscutae 7 parts, Rhizoma Dioscoreae 16 parts, Radix Polygoni Multiflori Preparata 18 parts, Caulis Spatholobi 8 parts, Fructus Lycii 8 parts, 5 parts, Radix Glycyrrhizae, Pericarpium Citri Reticulatae 4 parts, Radix Ophiopogonis 6 parts.
The invention provides a kind of pharmaceutical preparation for the treatment of myasthenia gravis in children:, described pharmaceutical preparation comprises foregoing Chinese medicine composition.
Further, the dosage form of described pharmaceutical preparation is the regular dosage form on pharmaceutics.Described dosage form includes but not limited to, tablet, capsule, pill, granule, suspensoid, powder, drop pill, oral liquid, injection, transfusion, lyophilized injectable powder, ointment, gel, patch, suppository etc.Preferred dosage form is peroral dosage form, such as tablet, capsule, pill, granule, syrup, mixture etc.
Further, described pharmaceutical preparation also comprises acceptable carrier on pharmaceutics, and on pharmaceutics of the present invention, acceptable carrier includes but not limited to:
Diluent: starch, Icing Sugar, lactose, dextrin, microcrystalline Cellulose, inorganic salt, sugar alcohols etc.
Wetting agent and binding agent: purified water, ethanol, gelatin, Polyethylene Glycol, cellulose derivative etc.
Disintegrating agent: starch, carboxymethyl starch sodium, cellulose derivative, polyvinylpolypyrrolidone etc.
Lubricant: magnesium stearate, micropowder silica gel, Pulvis Talci, Polyethylene Glycol etc.
Cosolvent: water, ethanol, glycerol, propylene glycol, liquid Paraffin, plant wet goods.
Correctives: sucrose, monosaccharide, aromatic etc.
Antiseptic: benzoic acid, sorbic acid, methyl ester, ethyl ester, propyl ester etc.
As required, can also add the adjuvant that other is suitable in production process, the application of these adjuvants is that formulation art is known.According to the needs of actual preparation, those skilled in the art can screen from existing pharmaceutical adjunct.
Chinese medicine composition of the present invention can be prepared by following method: by medical material clean, dry after, grind to form fine powder mix homogeneously, add suitable pharmaceutic adjuvant and be prepared into the acceptable any pharmacy types of pharmacy such as tablet, capsule, pill, granule.
Present invention also offers the preparation method of foregoing Chinese medicine composition, this preparation method comprises the steps: raw material of Chinese medicine to clean, dry, pulverize after add water, the conventional Extraction solvent such as ethanol extracts for several times, merge extractive liquid, filters, filtrate is condensed into cream.Then then cream is dry, pulverizing adds the acceptable any pharmacy types of pharmacy such as suitable pharmaceutic adjuvant standby one-tenth tablet, capsule, pill, electuary.
As interchangeable technical scheme, described preparation method comprises the steps: part raw material of Chinese medicine to clean, dry, pulverize after add water, the conventional Extraction solvent such as ethanol extracts for several times, merge extractive liquid, filters, filtrate is condensed into cream.Then cream is dry, pulverizing.Remainder raw material of Chinese medicine adopts to grind mix with cream powder and then adds suitable pharmaceutic adjuvant for becoming the acceptable any pharmacy types of pharmacy such as tablet, capsule, pill, electuary.
Chinese medicine composition of the present invention can also be prepared by the method for precipitate with ethanol after the most conventional decocting in water of the field of Chinese medicines or decocting in water.
Chinese medicine composition of the present invention can also adopt following preparation method: by raw material of Chinese medicine clean, dry after, grind to form fine powder mix homogeneously.
The invention provides the application of foregoing Chinese medicine composition in the medicine of preparation treatment myasthenia gravis in children:.
The invention provides the application of foregoing pharmaceutical preparation in the medicine of preparation treatment myasthenia gravis in children:.
Advantage of the present invention and beneficial effect as follows:
Chinese medicine composition abundance of the present invention, natural, preparation technology is simple, manufacturing cost is low, good effect, safety have no side effect, and is suitable for promoting the use of clinically.
Detailed description of the invention
In order to understand better and implement, further illustrate the present invention below in conjunction with embodiment.If no special instructions, embodiments of the invention only for explaining the present invention, and do not mean that restriction protection scope of the present invention.
Chinese medicine composition of the present invention and pharmaceutical preparation, under the prerequisite using theory of Chinese medical science basis, through scientific formula screening, under application Chinese crude drug takes the prerequisite of science extraction process, are refined and are processed.
The preparation of embodiment 1 Chinese medicine composition
1, the following raw material of Chinese medicine of precise: the Radix Astragali 10 parts, Radix Codonopsis 10 parts, the Rhizoma Atractylodis Macrocephalae 10 parts, Radix Bupleuri 5 parts, Rhizoma Cimicifugae 5 parts, Radix Angelicae Sinensis 5 parts, Fructus Corni 5 parts, Radix Morindae Officinalis 5 parts, Semen Cuscutae 5 parts, Rhizoma Dioscoreae 8 parts, Radix Polygoni Multiflori Preparata 6 parts, Caulis Spatholobi 5 parts, Fructus Lycii 5 parts, 3 parts, Radix Glycyrrhizae, Pericarpium Citri Reticulatae 3 parts, Radix Ophiopogonis 3 parts.
2, above-mentioned raw material of Chinese medicine is pulverized and mixed evenly.
The preparation of embodiment 2 Chinese medicine composition
1, the following raw material of Chinese medicine of precise: the Radix Astragali 120 parts, Radix Codonopsis 30 parts, the Rhizoma Atractylodis Macrocephalae 20 parts, Radix Bupleuri 8 parts, Rhizoma Cimicifugae 8 parts, Radix Angelicae Sinensis 10 parts, Fructus Corni 10 parts, Radix Morindae Officinalis 10 parts, Semen Cuscutae 10 parts, Rhizoma Dioscoreae 24 parts, Radix Polygoni Multiflori Preparata 30 parts, Caulis Spatholobi 12 parts, Fructus Lycii 12 parts, 6 parts, Radix Glycyrrhizae, Pericarpium Citri Reticulatae 6 parts, Radix Ophiopogonis 10 parts.
2, by the soak by water twice of above-mentioned each raw material of Chinese medicine quintuple, each two hours.Filter merging filtrate, standing getting after 48 hours after its supernatant concentrating under reduced pressure becomes clear paste is ground into fine powder, or concentrating under reduced pressure becomes thick paste.
The preparation of embodiment 3 Chinese medicine composition
1, the following raw material of Chinese medicine of precise: the Radix Astragali 60 parts, Radix Codonopsis 20 parts, the Rhizoma Atractylodis Macrocephalae 15 parts, Radix Bupleuri 6 parts, Rhizoma Cimicifugae 6 parts, Radix Angelicae Sinensis 7 parts, Fructus Corni 7 parts, Radix Morindae Officinalis 7 parts, Semen Cuscutae 7 parts, Rhizoma Dioscoreae 16 parts, Radix Polygoni Multiflori Preparata 18 parts, Caulis Spatholobi 8 parts, Fructus Lycii 8 parts, 5 parts, Radix Glycyrrhizae, Pericarpium Citri Reticulatae 4 parts, Radix Ophiopogonis 6 parts.
2, by the alcohol reflux three times of 85% of above-mentioned raw material of Chinese medicine triplication, each one hour.Merging filtrate, concentrating under reduced pressure is ground into fine powder after becoming clear paste, or concentrating under reduced pressure becomes thick paste.
The preparation of embodiment 4 pharmaceutical preparation
1, the preparation of oral liquid
(1) Chinese medicine composition clear paste is prepared according to the method in embodiment 1-embodiment 3;
(2) add 20% alcohol benzoate solution 5ml and 24% potassium sorbate solution 5ml, stir evenly, more than cold preservation 48h, filter, add water and be adjusted to every milliliter containing crude drug 5.5g, stir evenly, embedding, obtain oral liquid.
2, the preparation of syrup
(1) Chinese medicine composition clear paste is prepared according to the method in embodiment 1-embodiment 3;
(2) add adjuvant sucrose, sorbic acid, water stirs, obtained syrup.
3, the preparation of tablet
(1) Chinese medicine composition clear paste is prepared according to the method in embodiment 1-embodiment 3;
(2) supplementary product starch, ethanol, Pulvis Talci is added, obtained tablet.
4, the preparation of capsule
(1) Chinese medicine composition clear paste is prepared according to the method in embodiment 1-embodiment 3;
(2) add supplementary product starch, ethanol, dextrin, magnesium stearate, incapsulate shell, obtained capsule.
5, the preparation of granule
(1) Chinese medicine composition clear paste is prepared according to the method in embodiment 1-embodiment 3;
(2) adjuvant Icing Sugar, starch, dextrin, ethanol is added, obtained granule.
6, the preparation method of described pill comprises the following steps:
(1) Chinese medicine composition thick paste is prepared according to the method in embodiment 2-embodiment 3;
(2) paste is rolled into a ball into pellet, to obtain final product.
7, the preparation method of described mixture comprises the following steps:
(1) Chinese medicine extract thick paste is prepared according to the method in embodiment 1-embodiment 3;
(2) add adjuvant sucrose, ethyl ester, water, sorbic acid stir, obtained mixture.
The curative effect of embodiment 5 Chinese medicine composition
1, the preparation of experimental drug
Prepared by drugs compared A: take the Radix Astragali 60 parts, Radix Codonopsis 20 parts, the Rhizoma Atractylodis Macrocephalae 15 parts, 10 ~ 30 parts, Poria, Rhizoma Cimicifugae 10 parts, Radix Bupleuri 10 parts, Fructus Lycii 10 parts, Radix Angelicae Sinensis 10 parts, Pericarpium Citri Reticulatae 10 parts, Radix Glycyrrhizae Preparata 5 parts, Semen Cuscutae 10 parts, Semen Coicis 10 parts, 10 parts, Fructus Hordei Germinatus, Rhizomadioscoreae 10 parts, Fructus Corni 10 parts.With the soak by water twice of quintuple, each two hours, filter merging filtrate, leave standstill and get its supernatant concentrating under reduced pressure after 48 hours and become clear paste; Add 20% alcohol benzoate solution 5ml and 24% potassium sorbate solution 5ml, stir evenly, more than cold preservation 48h, filter, add water and be adjusted to every milliliter containing crude drug 5.5g, stir evenly, embedding, obtain oral liquid.
Prepared by drugs compared B: take the Radix Astragali 120 parts, Radix Pseudostellariae 20 parts, Radix Codonopsis 60 parts, the Rhizoma Atractylodis Macrocephalae 20 parts, Radix Bupleuri 6 parts, Rhizoma Cimicifugae 6 parts, Radix Angelicae Sinensis 7 parts, Rhizoma Dioscoreae 20 parts, Cortex Albiziae 6 parts, Radix Polygoni Multiflori Preparata 18 parts, Radix Morindae Officinalis 7 parts, Fructus Mori 6 parts, 5 parts, Radix Glycyrrhizae, Pericarpium Citri Reticulatae 4 parts, Fructus Aurantii 3 parts, Caulis Spatholobi 20 parts, Fructus Lycii 10 parts, Radix Ophiopogonis 6 parts.With the soak by water twice of quintuple, each two hours, filter merging filtrate.Leave standstill and get its supernatant concentrating under reduced pressure after 48 hours and become clear paste; Add 20% alcohol benzoate solution 5ml and 24% potassium sorbate solution 5ml, stir evenly, more than cold preservation 48h, filter, add water and be adjusted to every milliliter containing crude drug 5.5g, stir evenly, embedding, obtain oral liquid.
Chinese medicine composition preparation of the present invention: take the Radix Astragali 60 parts, Radix Codonopsis 20 parts, the Rhizoma Atractylodis Macrocephalae 15 parts, Radix Bupleuri 6 parts, Rhizoma Cimicifugae 6 parts, Radix Angelicae Sinensis 7 parts, Fructus Corni 7 parts, Radix Morindae Officinalis 7 parts, Semen Cuscutae 7 parts, Rhizoma Dioscoreae 16 parts, Radix Polygoni Multiflori Preparata 18 parts, Caulis Spatholobi 8 parts, Fructus Lycii 8 parts, 5 parts, Radix Glycyrrhizae, Pericarpium Citri Reticulatae 4 parts, Radix Ophiopogonis 6 parts.With the soak by water twice of quintuple, each two hours, filter merging filtrate, leave standstill and get its supernatant concentrating under reduced pressure after 48 hours and become clear paste; Add 20% alcohol benzoate solution 5ml and 24% potassium sorbate solution 5ml, stir evenly, more than cold preservation 48h, filter, add water and be adjusted to every milliliter containing crude drug 5.5g, stir evenly, embedding, obtain oral liquid.
2, crowd is tested: child patient number is 120 people, is divided into 3 groups at random, and all patients are all diagnosed as Patients With Myasthenia Gravis through following diagnostic criteria:
(1) neostigmine test is positive: electromyography repetitive nerve electric stimulation action potential is in decay.
(2) serum anti-acetylcholine antibody positive.
Give drugs compared A, drugs compared B, Chinese medicine composition of the present invention respectively,
Dosage is each 150-200ml, takes three day.Take continuously after one month and observe therapeutic effect.
3, efficacy assessment standard:
Cure: clinical symptoms and sign all disappear, three months without recurrence;
Effective: clinical symptoms and sign make moderate progress;
Invalid: clinical symptoms and sign are all without improvement.
4, efficacy result
Use the effective percentage of Chinese medicine composition of the present invention to reach 100%, effect is better than drugs compared A, drugs compared B, and concrete data ginseng is shown in Table 1.
Table 1 efficacy result is added up
Above content is in conjunction with concrete preferred implementation further description made for the present invention, can not assert that specific embodiment of the invention is confined to these explanations.For general technical staff of the technical field of the invention, without departing from the inventive concept of the premise, some simple deduction or replace can also be made, all should be considered as belonging to protection scope of the present invention.

Claims (10)

1. treat the Chinese medicine composition of myasthenia gravis in children: for one kind, it is characterized in that, described Chinese medicine composition is prepared from by the raw material of Chinese medicine of following weight: Radix Astragali 10-120 part, Radix Codonopsis 10-30 part, Rhizoma Atractylodis Macrocephalae 10-20 part, Radix Bupleuri 5-8 part, Rhizoma Cimicifugae 5-8 part, Radix Angelicae Sinensis 5-10 part, Fructus Corni 5-10 part, Radix Morindae Officinalis 5-10 part, Semen Cuscutae 5-10 part, Rhizoma Dioscoreae 8-24 part, Radix Polygoni Multiflori Preparata 6-30 part, Caulis Spatholobi 5-12 part, Fructus Lycii 5-12 part, Radix Glycyrrhizae 3-6 part, Pericarpium Citri Reticulatae 3-6 part, Radix Ophiopogonis 3-10 part.
2. Chinese medicine composition according to claim 1, it is characterized in that, described Chinese medicine composition is formulated by the raw material of Chinese medicine of following weight: the Radix Astragali 60 parts, Radix Codonopsis 20 parts, the Rhizoma Atractylodis Macrocephalae 15 parts, Radix Bupleuri 6 parts, Rhizoma Cimicifugae 6 parts, Radix Angelicae Sinensis 7 parts, Fructus Corni 7 parts, Radix Morindae Officinalis 7 parts, Semen Cuscutae 7 parts, Rhizoma Dioscoreae 16 parts, Radix Polygoni Multiflori Preparata 18 parts, Caulis Spatholobi 8 parts, Fructus Lycii 8 parts, 5 parts, Radix Glycyrrhizae, Pericarpium Citri Reticulatae 4 parts, Radix Ophiopogonis 6 parts.
3. treat a pharmaceutical preparation for myasthenia gravis in children:, it is characterized in that, described pharmaceutical preparation comprises the Chinese medicine composition described in claim 1 or 2.
4. pharmaceutical preparation according to claim 3, is characterized in that, the dosage form of described pharmaceutical preparation is the conventional oral dosage formulations on pharmaceutics.
5. pharmaceutical preparation according to claim 4, is characterized in that, described peroral dosage form is oral liquid, syrup, granule, pill, tablet, capsule, mixture.
6. the preparation method of the Chinese medicine composition described in claim 1 or 2, is characterized in that, described preparation method is as follows: by raw material of Chinese medicine clean, dry after, grind to form fine powder mix homogeneously.
7. the preparation method of the Chinese medicine composition described in claim 1 or 2, is characterized in that, described preparation method is as follows: raw material of Chinese medicine is cleaned, dries, pulverize after extract for several times, merge extractive liquid, filters, filtrate is condensed into cream, crushed after being dried mix homogeneously.
8. the preparation method described in claim 1 or 2, is characterized in that, described preparation method comprises the step by raw material of Chinese medicine decocting in water or water boiling and precipitation with ethanol.
9. the application of the Chinese medicine composition described in claim 1 or 2 in the medicine of preparation treatment myasthenia gravis in children:.
10. the application of the pharmaceutical preparation according to any one of claim 3-5 in the medicine of preparation treatment myasthenia gravis in children:.
CN201610129957.5A 2016-03-07 2016-03-07 Traditional Chinese medicine composition for treating children myasthenia gravis Active CN105535448B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610129957.5A CN105535448B (en) 2016-03-07 2016-03-07 Traditional Chinese medicine composition for treating children myasthenia gravis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610129957.5A CN105535448B (en) 2016-03-07 2016-03-07 Traditional Chinese medicine composition for treating children myasthenia gravis

Publications (2)

Publication Number Publication Date
CN105535448A true CN105535448A (en) 2016-05-04
CN105535448B CN105535448B (en) 2020-09-29

Family

ID=55815356

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610129957.5A Active CN105535448B (en) 2016-03-07 2016-03-07 Traditional Chinese medicine composition for treating children myasthenia gravis

Country Status (1)

Country Link
CN (1) CN105535448B (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107115483A (en) * 2017-05-02 2017-09-01 马宇振 It is a kind of to treat muscular dystrophy, the pharmaceutical composition of myasthenia and its application
CN108524748A (en) * 2018-07-13 2018-09-14 乞国艳 Treat the Chinese medicine composition that myasthenia gravis merges fash
CN108524775A (en) * 2018-07-13 2018-09-14 乞国艳 Application of the Chinese medicine in the pharmaceutical preparation for preparing treatment Myasthenia Gravis Associated with Thymoma
CN108653526A (en) * 2018-07-13 2018-10-16 乞国艳 The prescription of Chinese traditional treatment myasthenia gravis
CN111249437A (en) * 2020-04-20 2020-06-09 宋俊青 Traditional Chinese medicine formula for treating myasthenia gravis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104069339A (en) * 2014-06-18 2014-10-01 乞国艳 Traditional Chinese medicine composition for treating myasthenia gravis and preparation method thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104069339A (en) * 2014-06-18 2014-10-01 乞国艳 Traditional Chinese medicine composition for treating myasthenia gravis and preparation method thereof

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107115483A (en) * 2017-05-02 2017-09-01 马宇振 It is a kind of to treat muscular dystrophy, the pharmaceutical composition of myasthenia and its application
CN107115483B (en) * 2017-05-02 2020-09-29 马宇振 Pharmaceutical composition for treating muscular dystrophy and myasthenia and application thereof
CN108524748A (en) * 2018-07-13 2018-09-14 乞国艳 Treat the Chinese medicine composition that myasthenia gravis merges fash
CN108524775A (en) * 2018-07-13 2018-09-14 乞国艳 Application of the Chinese medicine in the pharmaceutical preparation for preparing treatment Myasthenia Gravis Associated with Thymoma
CN108653526A (en) * 2018-07-13 2018-10-16 乞国艳 The prescription of Chinese traditional treatment myasthenia gravis
CN108653526B (en) * 2018-07-13 2021-03-16 乞国艳 Traditional Chinese medicine formula for treating myasthenia gravis
CN108524775B (en) * 2018-07-13 2021-03-23 乞国艳 Application of traditional Chinese medicine in preparation of medicinal preparation for treating myasthenia gravis combined with thymoma
CN108524748B (en) * 2018-07-13 2021-05-14 乞国艳 Traditional Chinese medicine composition for treating myasthenia gravis combined with rash
CN111249437A (en) * 2020-04-20 2020-06-09 宋俊青 Traditional Chinese medicine formula for treating myasthenia gravis

Also Published As

Publication number Publication date
CN105535448B (en) 2020-09-29

Similar Documents

Publication Publication Date Title
EP0576456B1 (en) Pharmaceutical compositions for the treatment of skin disorders
Wang et al. Research progress in the treatment of slow transit constipation by traditional Chinese medicine
CN105535448A (en) Traditional Chinese medicine composition for treating child myasthenia gravis
WO2006060951A1 (en) A pharmaceutical composition for the treatment and/or prevention of hyperlipidemia, processes for producing the same and the use thereof
CN102119970B (en) Chinese medicinal composition for treating myasthenia gravis
CN105012452A (en) New application of clausena lansium leaves
US11160842B2 (en) Drug or health care product preventing or treating liver and kidney damage-related diseases and use thereof
CN102475830B (en) Medicinal composition for treating coronary disease and angina pectoris, preparation method thereof and preparation thereof
CN101933973B (en) Medicament composition for preventing and treating liver damage
Li et al. Botany, traditional usages, phytochemistry, pharmaceutical analysis, and pharmacology of Eleutherococcus nodiflorus (Dunn) SY Hu: A systematic review
CN102552527B (en) Traditional Chinese medicine composition used for treating diabetic complications and reducing blood sugar and preparation method thereof
CN110876772A (en) Preparation method and application of traditional Chinese medicine preparation with liver protection function
CN105250427A (en) Pharmaceutical composition for treating heart diseases
CN101199669A (en) Chinese medicine compound agent for treating female sperm quality lowclass
CN109876127B (en) Blood-nourishing angelica sinensis capsule and preparation method thereof
CN105477465A (en) Chinese herb preparation with liver protection function and preparing technology of Chinese herb preparation
CN1814250B (en) Chinese medicine composition for treating liver cirrhosis ascites and preparation method thereof
CN104306784A (en) Traditional Chinese medicine composition for treating rheumatoid arthritis as well as preparation method and application thereof
CN110279744A (en) A kind of liver protecting Chinese traditional compound medicine and preparation method thereof
CN104001041A (en) Traditional Chinese medicine for treating cerebral infarction
CN113101330B (en) Menstruation regulating composition and application thereof
CN114712470B (en) Medicine for treating deficiency of kidney of men and preparation method thereof
CN100571728C (en) A kind of method for preparing WANTONG JINGU PIAN
CN105194296A (en) Medicine composition for treating heart diseases
CN105641168A (en) Medicine for treating viral hepatitis B and viral hepatitis C and preparation method of medicine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant